Agreed. These are valid concerns, and I have been
Post# of 145787
![](/assets/46931549/no_avatar_available_thumb.jpg)
Is it possible that the confidence exhibited by our CytoDyn doctors (BP, JL, NP) is based entirely on "Other Outcome Measures" and less on "Primary Outcome Measures". As I understand it, they cannot really have any insight into the symptomatic improvement of these patients.
And is it possible this confidence is misplaced in terms of the metrics that the FDA are going to base their approval decision on?
This is a question I'd really like to pose to Dr. NP and Dr. JL.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)